
{{Act of Congress
| congress       = 113
| session        = 1
| title          = To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.
| year           = 2013
| month          = 02
| day            = 04
| bill           = 460
| billtype       = hr
| purpose        = To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 460}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|February 4, 2013}}


{{Center|
[[w:David McKinley|Mr. McKinley]] (for himself,
[[w:Lois Capps|Mrs. Capps]] ,
[[w:Shelley Moore Capito|Mrs. Capito]] ,
[[w:Bill Young|Mr. Young of Florida]] ,
[[w:Jim Moran|Mr. Moran]] ,
[[w:Frank Wolf|Mr. Wolf]] ,
[[w:Paul Tonko|Mr. Tonko]] ,
[[w:Jon Runyan|Mr. Runyan]] ,
[[w:John Conyers|Mr. Conyers]] ,
[[w:Suzanne Bonamici|Ms. Bonamici]] ,
[[w:David Cicilline|Mr. Cicilline]] ,
[[w:Peter DeFazio|Mr. DeFazio]] ,
[[w:Mike Michaud|Mr. Michaud]] ,
[[w:Sam Farr|Mr. Farr]] ,
[[w:Chellie Pingree|Ms. Pingree of Maine]] ,
[[w:Charles B. Rangel|Mr. Rangel]] , and
[[w:Ander Crenshaw|Mr. Crenshaw]] ) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}


{{Center|A BILL}}

To amend title XXVII of the Public Health Service Act to limit co-payment, coinsurance, or other cost-sharing requirements applicable to prescription drugs in a specialty drug tier to the dollar amount (or its equivalent) of such requirements applicable to prescription drugs in a non-preferred brand drug tier, and for other purposes.

={{anchor|H0BF352CBC51343DFAF57AB52258BD5DC}}Section 1. Short title=

This Act may be cited as the“Patients’ Access to Treatments Act of 2013”.

={{anchor|H9B023CBC47494D5B9817A070E06C5272}}Sec. 2. Cost-sharing requirements applicable to prescription drugs in a specialty drug tier=



=={{anchor|HF20A42F24D3442AEB5E84D5D4AC4C5C5}}(a) In general– ==

 Subpart II of part A of title XXVII of the Public Health Service Act([http://www.law.cornell.edu/uscode/text/42/300gg 42 U.S.C. 300gg et seq.] )is amended by adding at the end the following:

<blockquote>

=={{anchor|H44961867F4914BFD94FD2BBB06C3C530}}Sec. 2719B. Cost-sharing requirements applicable to prescription drugs in a specialty drug tier==



==={{anchor|H5E191DE53A354E99876A7F1CB0BAD474}}(a) Requirement– ===

A group health plan, or a health insurance issuer offering group or individual health insurance, that provides coverage for prescription drugs and uses a formulary or other tiered cost-sharing structure shall not impose cost-sharing requirements applicable to prescription drugs in a specialty drug tier that exceed the dollar amount (or its equivalent) of cost-sharing requirements applicable to prescription drugs in a non-preferred brand drug tier (or prescription drugs in a brand drug tier if there is no non-preferred brand drug tier).

==={{anchor|H46C62FC406244BA8B3F6AA3560E7D218}}(b) Special rule– ===

If a formulary used by a group health plan or a health insurance issuer offering group or individual health insurance contains more than one non-preferred brand drug tier, then the requirements of subsection (a)shall be applied with respect to the non-preferred brand drug tier for which beneficiary cost-sharing is lowest.

==={{anchor|H4833924F8E2C46CBB09AFBF743C84A9A}}(c) Definitions– ===

In this section:
:(1) The term cost-sharing includes co-payment and coinsurance.
:(2) The term drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other cost-sharing structure, a category of drugs—
::(A) within such formulary or structure for which the total dollar amount of cost-sharing requirements for any drug does not vary by more than ten percent from the total dollar amount of cost-sharing requirements for any other drug; and
::(B) that are prescription drugs.
:(3) The term non-preferred brand drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—
::(A) within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs or preferred brand drugs in the formulary or structure;
::(B) that are prescription drugs; and
::(C) that are not included within a specialty drug tier.
:(4) The term prescription drug means—
::(A) a drug subject to section 503(b)(1) of the Federal Food, Drug, or Cosmetic Act; and
::(B) includes a drug described in subparagraph (A)that is a biological product (as defined in section 351(i) of this Act).
:(5) The term specialty drug tier means, with respect to a group health plan or health insurance issuer offering group or individual health insurance coverage that uses a formulary or other tiered cost-sharing structure, a category of drugs—
::(A) within a drug tier in such formulary or structure for which beneficiary cost-sharing is greater than drug tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan’s formulary; and
::(B) that are prescription drugs..
</blockquote>


=={{anchor|HA1A831C9A11744249ECD2795B39E1232}}(b) Effective date– ==

 Section 2719B of the Public Health Service Act, as added by subsection (a), applies to plan years beginning on or after the date of the enactment of this Act.